NCT01858831View on ClinicalTrials.gov

Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Malaria

Interventions

DRUG

Atovaquone/proguanil HCL

Atovaquone/proguanil HCL

DRUG

Atovaquone

Atovaquone

Trial Locations (1)

890-0081

GSK Investigational Site, Kagoshima

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01858831 - Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension | Biotech Hunter | Biotech Hunter